Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.04B |
| 2 |
Chevron
CVX
|
+$820M |
| 3 |
Shopify
SHOP
|
+$599M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$539M |
| 5 |
Meta Platforms (Facebook)
META
|
+$479M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$675M |
| 2 |
Tesla
TSLA
|
+$661M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$633M |
| 4 |
Verizon
VZ
|
+$533M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$377M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.47% |
| 2 | Technology | 16.84% |
| 3 | Consumer Staples | 11.12% |
| 4 | Consumer Discretionary | 10.18% |
| 5 | Financials | 8.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
iShares US Home Construction ETF
ITB
$2.37B
| $2.09M | ﹤0.01% |
39,800
-12,200
| -23% | -$697K |
|
|
DAWN
2152
DELISTED
Day One Biopharmaceuticals
DAWN
| $2.09M | ﹤0.01% |
+116,630
| New | +$1.2M |
|
2153
SiTime
SITM
$20.7B
| $2.09M | ﹤0.01% |
12,800
-100,000
| -89% | -$18.9M |
|
2154
Security National Financial
SNFCA
$242M
| $2.08M | ﹤0.01% |
299,631
-26,740
| -8% | -$194K |
|
|
AVDL
2155
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.08M | ﹤0.01% |
854,006
+99,700
| +13% | +$409K |
|
|
GES
2156
DELISTED
Guess Inc
GES
| $2.08M | ﹤0.01% |
+122,100
| New | +$2.54M |
|
|
LUMO
2157
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $2.08M | ﹤0.01% |
270,112
-1,600
| -0.6% | -$12.8K |
|
2158
Sypris Solutions
SYPR
$46.8M
| $2.08M | ﹤0.01% |
894,532
-3,500
| -0.4% | -$7.9K |
|
2159
iShares MSCI Intl Quality Factor ETF
IQLT
$14.3B
| $2.07M | ﹤0.01% |
+66,900
| New | +$2.25M |
|
2160
Vanguard Morningstar Small-Cap Growth ETF
VBK
$24.9B
| $2.07M | ﹤0.01% |
10,500
+9,400
| +855% | +$2.04M |
|
|
PMD
2161
DELISTED
Psychemedics Corporation
PMD
| $2.07M | ﹤0.01% |
326,167
-15,255
| -4% | -$97.7K |
|
|
MGI
2162
DELISTED
MoneyGram International, Inc. New
MGI
| $2.07M | ﹤0.01% |
206,800
-33,649
| -14% | -$339K |
|
2163
Lifeway Foods
LWAY
$447M
| $2.07M | ﹤0.01% |
415,672
-988
| -0.2% | -$5.5K |
|
|
KE
2164
Kimball Electronics
KE
$606M
| $2.06M | ﹤0.01% |
102,650
-77,400
| -43% | -$1.46M |
|
|
IVAC
2165
DELISTED
Intevac Inc
IVAC
| $2.06M | ﹤0.01% |
425,892
-25,828
| -6% | -$132K |
|
2166
Accel Entertainment
ACEL
$1B
| $2.06M | ﹤0.01% |
193,900
+119,200
| +160% | +$1.33M |
|
|
BRY
2167
DELISTED
Berry Corp
BRY
| $2.06M | ﹤0.01% |
269,900
+15,340
| +6% | +$162K |
|
|
HNGR
2168
DELISTED
Hanger Inc.
HNGR
| $2.05M | ﹤0.01% |
143,291
+3,800
| +3% | +$61.6K |
|
2169
Aldeyra Therapeutics
ALDX
$91.7M
| $2.05M | ﹤0.01% |
+514,100
| New | +$1.77M |
|
2170
Karyopharm Therapeutics
KPTI
$45.1M
| $2.05M | ﹤0.01% |
30,320
+15,980
| +111% | +$1.47M |
|
2171
Transcat
TRNS
$888M
| $2.05M | ﹤0.01% |
+36,100
| New | +$2.5M |
|
2172
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$11.6B
| $2.05M | ﹤0.01% |
62,700
+27,000
| +76% | +$893K |
|
2173
Alignment Healthcare
ALHC
$2.79B
| $2.04M | ﹤0.01% |
179,200
+56,400
| +46% | +$595K |
|
2174
Jakks Pacific
JAKK
$288M
| $2.04M | ﹤0.01% |
161,418
+5,400
| +3% | +$71.5K |
|
2175
Cardlytics
CDLX
$24.7M
| $2.04M | ﹤0.01% |
9,154
+880
| +11% | +$295K |
|
Similar funds
Jim Simons's Q2 2022 Portfolio in Review
As of Q2 2022, Jim Simons held 4,738 positions worth $84.5B, down 0.87% from $85.2B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $13.7B of net new capital in Q2 2022, opening 694 new positions and adding to 1,955 existing holdings. Its largest new stake was Microsoft: 3,820,133 shares worth $981M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Tesla, an estimated $661M trimmed.
- Jim Simons's largest Q2 2022 buy was Microsoft: 3,820,133 shares worth $981M.
- Jim Simons added most to Chevron in Q2 2022, an estimated $820M increase.
- Jim Simons's biggest Q2 2022 reduction was Tesla, cutting an estimated $661M.
- Jim Simons fully exited Amazon in Q2 2022, selling an estimated $675M.
- Jim Simons's ten largest holdings make up 11% of its $84.5B portfolio in Q2 2022.
- Jim Simons opened 694 new positions and closed 562 in Q2 2022.
- Jim Simons's portfolio value fell 0.87% quarter-over-quarter to $84.5B.
Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.